Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CorMedix Inc. (CRMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.0700+0.2200 (+5.71%)
At close: 04:00PM EST
4.0700 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.8500
Open3.9300
Bid4.0600 x 800
Ask4.0700 x 800
Day's Range3.7000 - 4.0800
52 Week Range3.7000 - 18.8000
Volume203,991
Avg. Volume202,838
Market Cap155.012M
Beta (5Y Monthly)2.47
PE Ratio (TTM)N/A
EPS (TTM)-0.7310
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
  • GlobeNewswire

    CorMedix to Participate in Upcoming January Conferences

    BERKELEY HEIGHTS, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will be participating in several upcoming investor conferences in January. Investor Conference Details LifeSci Partners – 11th Annual Corporate Access Event Wednesday, January 5th – Friday, January 7th To re

  • GlobeNewswire

    CorMedix Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

    Conference Call Scheduled for Today at 4:30 p.m. Eastern TimeBERKELEY HEIGHTS, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the third quarter and nine months ended September 30, 2021 and provided an update on recent developments. Recent Corporate and Regulatory Highlights:

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Live Ventures, CorMedix, Emergent BioSolutions, and Generac on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Live Ventures Incorporated (NASDAQ: LIVE), CorMedix Inc. (NASDAQ: CRMD), Emergent BioSolutions, Inc. (NYSE: EBS), and Generac Holdings Inc. (NYSE: GNRC) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Live Ventures Incorporated (NASDAQ: LIVE) Bragar Eagel

Advertisement
Advertisement